In brief
- The final analysis of the single-arm Phase 2 PECATI trial reports a median progression-free survival (PFS) of 22.1 months with lenvatinib plus pembrolizumab in 43 patients with platinum-refractory B3 thymoma or thymic carcinoma.
- Median overall survival (OS) was 40.2 months after a median follow-up of 24.6 months, and 53.0% of patients were alive at 36 months.
- The confirmed objective response rate (ORR) was 25.6%, and the median duration of response was not reached.
- Grade 3 or higher treatment-related adverse events occurred in 44.2% of patients and led to discontinuation in 27.9%.
- The trial had already met its primary endpoint, a 5-month PFS rate of 88.0%; there is still no standard second-line treatment in this setting.
Study at a glance
- Trial: PECATI (NCT04710628), single-arm Phase 2
- Population: 43 patients with metastatic B3 thymoma or thymic carcinoma, progressed after at least one platinum-based chemotherapy, no autoimmune disorders
- Treatment: lenvatinib 20 mg orally once daily plus pembrolizumab 200 mg intravenously every 3 weeks, for up to 35 cycles
- Primary endpoint: 5-month PFS rate, 88.0% (met)
- PFS: median 22.1 months after a median follow-up of 24.6 months
- Survival: median OS 40.2 months; 36-month OS rate 53.0%
- Response: confirmed ORR 25.6%; median duration of response not reached
- Safety: grade 3 or higher treatment-related adverse events in 44.2%; discontinuation for toxicity in 27.9%
A mostly thymic carcinoma population with extensive disease
The 43 patients enrolled had a median age of 57 years, with a range of 33 to 81. Thymic carcinoma accounted for 84% of them, so the results speak mainly to that histology and much less to B3 thymoma. Disease was extensive: 65% had Masaoka-Koga stage IVB tumours and 51.2% had three or more metastatic sites.
Almost half the cohort, 44.2%, had received two or more prior lines of therapy for advanced disease. Patients with autoimmune disorders were excluded, so the results do not apply to patients with thymic tumours who also have an autoimmune condition.
Median PFS of 22 months after platinum failure
The trial had already reported meeting its primary endpoint, with 88.0% of patients free of progression at 5 months. With a median follow-up of 24.6 months, the final analysis puts the median PFS at 22.1 months.
Median OS reached 40.2 months, although the upper bound of its confidence interval could not be estimated, and 53.0% of patients were alive at 36 months. All of these figures come from one arm without a comparator, in a rare cancer with no agreed standard second-line regimen against which they could be judged.
A response rate of about one in four, median duration not yet reached
The confirmed ORR was 25.6%. The median duration of response had not been reached at the final analysis, after a median follow-up of 24.6 months. The abstract does not report the disease control rate, so the share of patients whose disease was stabilised without shrinking cannot be read from it.
“The final results of PECATI trial supports the combination lenvatinib plus pembrolizumab as a potential treatment option in pre-treated advanced B3-thymoma and thymic carcinoma.”Remón et al., Journal of Thoracic Oncology (2026)
Treatment-related toxicity of grade 3 or higher in 44% of patients
Grade 3 or higher treatment-related adverse events occurred in 44.2% of patients and led to discontinuation in 27.9%. Grade 3 immune-related adverse events were recorded in 11.6%. Two grade 5 events (4.7%) occurred, and both were judged not to be related to treatment.
The authors describe the toxicity profile as manageable but advise close monitoring. More than a quarter of patients stopping treatment for toxicity is a substantial rate for a regimen intended to be given for up to 35 cycles. The abstract does not break the treatment-related events down by type, and it does not say how often the lenvatinib dose was reduced or interrupted.
Sources
- Journal of Thoracic Oncology. Final Analysis From PECATI Phase 2 Trial: Lenvatinib in Combination With Pembrolizumab in Pretreated Advanced B3 Thymoma and Thymic Carcinoma (2026-11-01). doi.org
Featuring Lung Summit faculty
This study was co-authored by Lung Summit faculty Jordi Remon, Nicolas Girard and Noemí Reguart.
This article was produced independently by the Lung Summit editorial team, without industry funding or input.